Loading clinical trials...
Loading clinical trials...
A Phase IB/II Study To Evaluate the Safety, Tolerability, and Preliminary Efficacy of HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
Conditions
Interventions
HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine
HRS-4642;nab-paclitaxel; gemcitabine
Locations
1
China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Start Date
January 8, 2026
Primary Completion Date
October 1, 2027
Completion Date
December 1, 2027
Last Updated
January 14, 2026
Lead Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions